Hydrogen Bromide → 5-((2R,4R)-2-(3,4-difluorobenzyl)piperidin-4-yl)isoxazol-3(2H)-one
Reaction equation
[F:1][C:2]1[CH:3]=[C:4]([CH:22]=[CH:23][C:24]=1[F:25])[CH2:5][C@H:6]1[CH2:11][C@H:10]([C:12]2[O:16][NH:15][C:14](=[O:17])[CH:13]=2)[CH2:9][CH2:8][N:7]1C(OC)=O.Br>>[F:1][C:2]1[CH:3]=[C:4]([CH:22]=[CH:23][C:24]=1[F:25])[CH2:5][C@H:6]1[CH2:11][C@H:10]([C:12]2[O:16][NH:15][C:14](=[O:17])[CH:13]=2)[CH2:9][CH2:8][NH:7]1Participants
Procedure
(2R,4R)-Methyl 2-(3,4-difluorobenzyl)-4-(3-oxo-2,3-dihydroisoxazol-5-yl)piperidine-1-carboxylate (32.5 mg, 0.09 mmol) was dissolved in hydrogen bromide (33% in acetic acid, 0.8 mL, 4.57 mmol) and the mixture stirred at room temperature overnight. The solvent was evaporated and the residue purified by preparative HPLC (Instrument: FractionLynx III, Mobilphase: gradient 5-95% MeCN in 0.2% NH3, pH 10, Column: Xbridge Prep C18 5 μm OBD 19*150 mm) to yield 5-((2R,4R)-2-(3,4-difluorobenzyl)piperidin-4-yl)isoxazol-3(2H)-one (10.4 mg, 38%). 1H NMR (600 MHz, cd3od) δ 1.71-1.78 (m, 1H), 1.96-2.04 (m, 1H), 2.05-2.12 (m, 2H), 2.80-2.92 (m, 2H), 2.96-3.03 (m, 1H), 3.15-3.25 (m, 2H), 3.26-3.35 (m, 1H), 5.50 (s, 1H), 6.99-7.05 (m, 1H), 7.13-7.23 (m, 2H). HRMS Calculated for [C15H16F2N2O2+H]+: 295.1258. Found: 295.1267
Workup
- customThe solvent was evaporated
- customthe residue purified by preparative HPLC (Instrument: FractionLynx III, Mobilphase: gradient 5-95% MeCN in 0.2% NH3, pH 10, Column: Xbridge Prep C18 5 μm OBD 19*150 mm)
Sources & evidence
- ORD record
- ord-9dca74e724bc4bb78fc16316ab4f1442
- Source dataset
- uspto-grants-2013_04
- Patent number
- US08415378B2
Reaction notes
Loading…